Alkem Laboratories Q2 Results 2026: PAT ₹667 Cr, Revenue ₹4,552 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹4,552Cr
- Net profit
- ₹667Cr
- Margin
- 22.5%
Guidance rank: #61 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Alkem Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY.
As stated in Alkem Laboratories Ltd's Q2 FY27 investor presentation · published 12 Nov 2026. Reported figures, not investment advice.
Based on Alkem Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. EBITDA for Q2 FY27: ₹10,252 million.
From Alkem Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Alkem Laboratories' revenue grow in the September 2026 quarter?
- Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY.
- India sales: ₹30,275 million, up 9.5% YoY.
- International sales: ₹14,540 million, up 22.3% YoY.
- US sales: ₹7,830 million, up 2.4% YoY.
- Non-US international sales: ₹6,710 million, up 58% YoY.
- Biotech sales: ₹704 million, down 35% YoY.
- MedTech sales (including Occlutech): ₹1,331 million.
2 more points from Alkem Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Alkem Laboratories' margins in Q2 FY27?
See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Alkem Laboratories planning?
- Facility Regulatory Status (Page 3):
- - Daman formulations facility (India): Received OAI in Aug 2026; response submitted; remediation in progress.
- - Mandva (India) API plant: Successful US FDA inspection in Oct 2026 with zero observations.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Alkem Laboratories raising money or cutting debt?
See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Alkem Laboratories' order book?
See what Alkem Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Alkem Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Alkem Laboratories Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 4,552 |
| Operating profit (EBITDA) | 1,025 |
| Operating margin | 22.5% |
| Profit before tax | 1,000 |
| Net profit (PAT) | 667 |
| EPS (₹) | 56.48 |
Source: Alkem Laboratories Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹3.7K Cr, net profit ₹521 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Alkem Lab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Caplin Point Laboratories Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor
- Ortin Global (Q2 FY27)
This represents a year-on-year increase of Rs 1.74 lakhs (approximately 124.3% increase). Key results statement takeaways from Ortin Global Ltd's Q2 FY27 result
- Bal Pharma (Q2 FY27)
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…
- Bafna Pharmaceuticals (Q2 FY27)
INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alkem Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alkem Laboratories Ltd Q2 FY27 results?
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. EBITDA for Q2 FY27: ₹10,252 million.
What is Alkem Laboratories Ltd share price analysis?
Alkem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 28.8 with a market cap of ₹65,532 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.